루이소체치매(LBD) : 출시 의약품 및 파이프라인 의약품 평가, 임상시험, 경쟁 현황
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
상품코드
:
1284036
리서치사
:
GlobalData
발행일
:
2023년 05월
페이지 정보
:
영문 67 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
이 보고서는 루이소체치매(LBD, Lewy Body Dementia) 임상시험 시장에 대해 조사했으며, 시장 개요와 함께 출시 의약품 및 파이프라인 의약품, 임상시험 동향, 주요 기업, 향후 시장 성장 촉진요인 등에 대해 조사하여 전해드립니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질환 상황
제4장 출시 의약품 평가
- 주요 출시 의약품
- 작용기전별 개요
- 투여 경로별 개요
- 시판약 개요와 판매 예측
제5장 가격 결정과 상환 평가
제6장 파이프라인 의약품 평가
- 3상 파이프라인 의약품
- 개발 단계별 개요
- 분자 유형별 개요
- 작용기전별 개요
- 투여 경로별 개요
- 의약품 고유의 단계 전환 성공률(PTSR)과 승인 가능성(LoA)
- 치료 영역 및 적응증 고유의 PTSR 및 LoA
제7장 임상시험 평가
- 과거 개요
- 상별 개요
- 시험 상황별 개요
- 진행중 및 계획중인 임상시험 단계별 개요
- 가상 컴포넌트를 사용한 임상시험
- 지리적 개요
- 지역별 단일국 및 다국적 임상시험
- 상위 20개 스폰서와 단계별 내역
- 상위 20개 스폰서 시험 상황별 내역
- 엔드포인트 시험 상황별 개요
- 인종 및 민족별 개요
- 등록 데이터
- 임상시험 사이트 상위 20개국
- 세계의 TOP 20 사이트
- 실현 가능성 분석 - 지리적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
제9장 상업적 평가
제10장 향후 시장 성장 촉진요인
제11장 부록
LSH
영문 목차
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in LBD therapeutics.
- There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData's epidemiology forecast.
- Currently, there are three marketed products for the treatment of LBD.
- R&D activity within the LBD space is negligible, with no pipeline products in late-stage clinical development.
- Commercial sponsors dominate clinical trial development in LBD, with the US and the UK emerging as the key countries for conducting trials in this disease space.
- Deals involving partnerships were the most common type of deals globally involving companies developing LBD assets.
Scope
GlobalData's LBD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the LBD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LBD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
관련자료
